We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Novel ELISA Detects Invasive Aspergillosis

By LabMedica International staff writers
Posted on 05 Sep 2019
Aspergillus spp. is a ubiquitous sac fungus, which is found in soil or compost or on damp walls. Inhalation of spores can lead to severe infections in individuals with a weakened immune system.

In invasive aspergillosis (IA) the fungus spreads from the lungs to other parts of the body such as the nervous system, eyes, heart, kidneys and skin. Infections affecting the nervous system are nearly always fatal. Patients with neutropenia, leukaemia, or septic granulomatosis are especially at risk of IA.

Invasive aspergillosis is also a frequent complication in advanced AIDS or following chemotherapy or bone marrow or organ transplants. Early diagnosis and prompt treatment are crucial for survival. Since clinical and radiological signs of IA are often non-specific, additional diagnostics tests such as antigen detection and culture are nearly always required to substantiate diagnosis.

A CE-marked assay, Aspergillus Antigen ELISA (EUROIMMUN, Luebeck, Germany) is based on a monoclonal antibody for the detection of the Aspergillus-specific galactomannoprotein, which is produced during active fungal growth. The analysis is performed on patient serum or bronchoalveolar lavage (BAL) fluid. Results can be evaluated either quantitatively in pg/mL using a six-point calibration curve or semi-quantitatively by means of a cut-off ratio. Semi-automated processing is available, for example using the EUROIMMUN Analyzer I.

In the most comprehensive clinical study to date, carried out by the Ludwig-Maximilians-Universität München (Munich, Germany) based on 120 sera from 45 patients with proven IA as well as control sera, the EUROIMMUN Aspergillus Antigen ELISA yielded comparable sensitivity and specificity to another commercially available Aspergillus antigen test the Platelia Aspergillus Ag Assay. The EUROIMMUN assay identified 56% of the cases, while the Bio-Rad test detected 47%. The specificity amounted to 97% for the EUROIMMUN assay and 99% for the Bio-Rad test. To overcome the relatively low sensitivity of Aspergillus antigen detection, the authors recommend serial testing of patients at risk. The original study was published on June 25, 2019, in the Journal of Clinical Microbiology.


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.